|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-7-14
|
|
pubmed:abstractText |
A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:CutzJean-ClaudeJC,
pubmed-author:DaneshmandManijehM,
pubmed-author:DingKeyueK,
pubmed-author:Kamel-ReidSuzanneS,
pubmed-author:LagardeAlainA,
pubmed-author:LiuNiN,
pubmed-author:LorimerIanI,
pubmed-author:MarranoPaulaP,
pubmed-author:PaterJosephJ,
pubmed-author:RichardsonFrankF,
pubmed-author:SakuradaAkiraA,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrances AFA,
pubmed-author:SquireJeremyJ,
pubmed-author:TsaoMing-SoundMS,
pubmed-author:WhiteheadMarloM,
pubmed-author:ZhangTongT,
pubmed-author:ZhuChang-QiCQ,
pubmed-author:da Cunha SantosGildaG
|
|
pubmed:copyrightInfo |
Copyright 2005 Massachusetts Medical Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
14
|
|
pubmed:volume |
353
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
133-44
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16014883-Adenocarcinoma,
pubmed-meshheading:16014883-Adult,
pubmed-meshheading:16014883-Aged,
pubmed-meshheading:16014883-Aged, 80 and over,
pubmed-meshheading:16014883-Analysis of Variance,
pubmed-meshheading:16014883-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16014883-DNA Mutational Analysis,
pubmed-meshheading:16014883-Female,
pubmed-meshheading:16014883-Gene Expression,
pubmed-meshheading:16014883-Humans,
pubmed-meshheading:16014883-Lung Neoplasms,
pubmed-meshheading:16014883-Male,
pubmed-meshheading:16014883-Middle Aged,
pubmed-meshheading:16014883-Mutation,
pubmed-meshheading:16014883-Protein Kinase Inhibitors,
pubmed-meshheading:16014883-Quinazolines,
pubmed-meshheading:16014883-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16014883-Survival Analysis
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
|
|
pubmed:affiliation |
University Health Network, Princess Margaret Hospital Site, and the Ontario Cancer Institute, University of Toronto, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
